Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terbinafine
Drug ID BADD_D02160
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
Marketing Status OTC; Discontinued; Prescription
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02375
MeSH ID D000077291
PubChem ID 1549008
TTD Drug ID D01AYJ
NDC Product Code 72189-243; 63187-213; 69097-859; 59349-0008; 70518-1191; 76282-209; 62135-572; 71335-1668; 71205-152
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H25N
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.002117%Not Available
Photosensitivity reaction23.03.09.0030.001058%
Platelet count decreased13.01.04.001--
Pleural effusion22.05.02.0020.000552%
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polyarthritis15.01.01.0050.001058%Not Available
Presyncope17.02.05.009; 02.01.02.007; 24.06.02.0100.001764%
Protein total decreased13.09.01.0040.001058%Not Available
Proteinuria20.02.01.0110.000706%
Pruritus23.03.12.0010.017992%
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulse pressure increased13.14.04.0070.000706%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.000706%
Pustular psoriasis23.03.14.0060.005997%Not Available
Pyrexia08.05.02.0030.015523%
Rash23.03.13.0010.019756%Not Available
Rash erythematous23.03.06.0030.009525%Not Available
Rash generalised23.03.13.0020.008467%Not Available
Rash macular23.03.13.0030.001764%Not Available
Rash maculo-papular23.03.13.0040.004939%
Rash morbilliform23.03.13.0050.000706%Not Available
Rash papular23.03.13.0170.001058%Not Available
Rash pruritic23.03.12.0020.004939%Not Available
Rash pustular23.03.10.003; 11.01.12.0020.008114%
Raynaud's phenomenon24.04.03.0030.001058%Not Available
Renal colic20.02.03.0100.000706%
Renal disorder20.01.02.0020.001058%Not Available
Renal failure20.01.03.005--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 13 Pages